CRCbioscreen develops a novel, multi-target Faecal Immunochemical Test (mt FIT) for colorectal cancer screening. This stool-based test is designed to improve sensitivity for high-risk precursor lesions compared to current methods. The technology maintains the established low false-positive rate associated with standard FIT screening protocols.
Funding
Funding not disclosed
Founders
Product
Problem
Current fecal immunochemical tests (FIT) for colorectal cancer screening may lack the sensitivity needed to detect high-risk precursor lesions, potentially leading to delayed diagnoses and reduced effectiveness in lowering mortality rates.
Solution
CRCbioscreen is developing a next-generation, multi-target fecal immunochemical test (mt-FIT) designed to improve the early detection of colorectal cancer and its high-risk precursor lesions. This stool-based assay incorporates a novel combination of protein biomarkers to enhance sensitivity compared to traditional FIT methods. By identifying these lesions at an earlier stage, the mt-FIT aims to enable more timely intervention and ultimately reduce mortality associated with colorectal cancer. The technology is based on intellectual property licensed from the Netherlands Cancer Institute.
Target Audience
The primary target audience includes healthcare providers, screening programs, and individuals at risk for colorectal cancer who would benefit from more sensitive early detection methods.
Features
- Multi-target approach utilizing a combination of novel protein biomarkers.
- Stool-based assay for non-invasive colorectal cancer screening.
- Enhanced sensitivity for detecting high-risk precursor lesions.